A Single Exposure Clinical Trial to Evaluate the Dose Duration Response of Mometasone Furoate Cream and Vasoconstrictive Activity of MK0887G Topically applied to the skin of Healthy Subjects

Part 1 Treatment: Mometasone Furoate Cream (0.1%) 20mg/application site (5mg/cm2), single dose topical All participants will receive the above treatment applied to a total of 16 sites (2x2cm2) on the inner aspect of their forearms (8 per arm). Four additional sites will be marked but will remain untreated to act as non-dosed control sites. Mometasone furoate cream will be applied to test sites at staggered timepoints followed by synchronized removal from all test sites to achieve treatment durations of 15, 30, 45, 60, 90, 120, 240 & 360 minutes. Part 2 Treatments: Reference Treatment: Mometasone Furoate Cream (0.1%), 20mg per application site (5mg/cm2), single dose topical Test Treatment: MK-0887G 20mg/application site (5mg/cm2), single dose, topical All subjects will receive the same treatments which includes both the reference and test treatments as well as untreated control sites across a total of 20 sites (2cm x 2cm) marked on the volar aspect of the forearms (10 sites per arm). The reference and test treatments will be applied to test sites at staggered time points followed by synchronized removal from all test sites to achieve treatment durations (3 different durations for mometasone furoate and a single duration for MK0887G). The durations for the treatments have not yet been identified but will be deduced from the results of part 1 of the study. The position of reference and test treatment sites will be determined by the randomization code. MK0887G (fixed dose cream) is being developed for the treatment of infected dermatoses. However, this study is in healthy volunteers only.